{"id":48204,"date":"2022-09-10T13:01:42","date_gmt":"2022-09-10T11:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/"},"modified":"2022-09-10T13:01:42","modified_gmt":"2022-09-10T11:01:42","slug":"exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/","title":{"rendered":"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer"},"content":{"rendered":"
\n

\n\u2013 Poster presentation at the 2022 Annual Meeting of the European Society of Medical Oncology (ESMO), Paris, France<\/i>\n<\/p>\n

PALO ALTO, Calif.–(BUSINESS WIRE)–#innovation<\/a>–Exai Bio, a next-generation liquid biopsy company, and researchers at UCSF are presenting data from a new study in a poster entitled \u201cSerum-based colorectal cancer detection using orphan noncoding RNAs\u201d at the 2022 European Society of Medical Oncology (ESMO) meeting. This case-control study of 191 subjects demonstrated that Exai\u2019s novel, RNA-based platform accurately predicted colorectal cancer (CRC) cases versus non-cancer controls, both overall and across the full ranges of cancer stages and categories of tumor size\/extent.\n<\/p>\n

<\/a><\/p>\n

\nExai Bio\u2019s technology is based on using cell-free RNA sequencing to identify a novel class of cancer-associated small non-coding RNAs, termed orphan non-coding RNAs (oncRNAs). Exai has created a proprietary library of >250,000 oncRNAs found in several types of cancer. Because oncRNAs can be actively secreted by cancer cells, they are readily detectable in the blood of cancer patients and are largely absent in healthy individuals, making them potentially robust biomarkers with high sensitivity and specificity. These features give the Exai Bio RNA-based platform \u2014 which uses artificial intelligence (AI) to identify cancer-specific patterns among thousands of oncRNAs \u2014 several scientific and practical advantages over tests that use circulating tumor-derived DNA in mutational, epigenomic, or fragmentomic analyses.\n<\/p>\n

\nIn the present poster, the Exai oncRNA-based model, which used machine learning, predicted CRC with a high overall sensitivity of 90.6% at 90% specificity. Predictions were also accurate for stage I cancer (92% sensitivity) and for the lowest categories of tumor size\/extent, T1\/T2 (92.3% sensitivity), indicating that even the earliest stage cancers and smallest tumors were detectable. Exai Bio is thus positioned to improve patient care by developing a variety of liquid biopsy blood tests for CRC, including for early detection and monitoring of residual disease or recurrence.\n<\/p>\n

\nPatrick Arensdorf, Chief Executive Officer of Exai Bio, commented, \u201cWe are truly excited about these findings. Exai Bio is working to fulfill unmet needs that exist despite recent advances in liquid biopsy testing. This work demonstrates that Exai Bio can measure novel biomarkers in blood-derived samples to accurately predict colorectal cancer, including the earliest-stage and smallest tumors. By achieving greater than 90% sensitivity at 90% specificity, we exceeded the sensitivity hurdle in the published CMS National Coverage Determination for blood-based biomarker tests in CRC screening1<\/sup>. Moreover, the oncRNA-based liquid biopsy technology will be compatible with standard sample requirements enabling easy integration into conventional clinical workflows. These results build on our earlier study<\/a> in breast cancer and validate the applicability of cell-free RNA methods in yet another tumor type.\u201d\n<\/p>\n

    \n
  1. \nNCD for Colorectal Cancer Screening Test (210.3). Medicare Coverage Decision database: Screening for Colorectal Cancer biomarker-based test: CAG-00454N decision memo 01\/19\/2021; cms.gov.\n<\/li>\n<\/ol>\n

    \nDetails of the ESMO 2022 eposter presentation:
    \n
    <\/b>Title: <\/b>Serum-based colorectal cancer detection using orphan noncoding RNAs
    \n
    Abstract category: <\/b>Biomarkers (agnostic)
    \n
    Abstract number<\/b>: 4635
    \n
    Authors:<\/b> Hani Goodarzi, Jeffrey Wang, Oluwadamilare I. Afolabi, Lisa Fish, Helen Li, Kimberly H. Chau, Patrick Arensdorf, Fereydoun Hormozdiari, Babak Alipanahi\n<\/p>\n

    \nPosters will be available on-demand on the EMSO website for attendees (www.emso.org<\/a>) beginning at 12:00 PM CEST on Friday, September 9, 2022 until Tuesday, September 13, 2022 Upon release at ESMO, the poster will be accessible on the publications page of the Exai Bio website<\/a>.\n<\/p>\n

    \nAbout Exai Bio<\/b>\n<\/p>\n

    \nExai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company\u2019s proprietary RNA and artificial intelligence-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.\n<\/p>\n

    Contacts<\/b> <\/p>\n

    \nFor more information: info@exai.bio<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    \u2013 Poster presentation at the 2022 Annual Meeting of the European Society of Medical Oncology (ESMO), Paris, France PALO ALTO, Calif.–(BUSINESS WIRE)–#innovation–Exai Bio, a next-generation liquid biopsy company, and researchers at UCSF are presenting data from a new study in a poster entitled \u201cSerum-based colorectal cancer detection using orphan noncoding RNAs\u201d at the 2022 European … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48204","6":"format-standard","7":"category-industry"},"yoast_head":"\nExai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 Poster presentation at the 2022 Annual Meeting of the European Society of Medical Oncology (ESMO), Paris, France PALO ALTO, Calif.–(BUSINESS WIRE)–#innovation–Exai Bio, a next-generation liquid biopsy company, and researchers at UCSF are presenting data from a new study in a poster entitled \u201cSerum-based colorectal cancer detection using orphan noncoding RNAs\u201d at the 2022 European ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-10T11:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220910005004\/en\/1566542\/21\/exai_bio_lockup%403x_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer\",\"datePublished\":\"2022-09-10T11:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/\"},\"wordCount\":624,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220910005004\\\/en\\\/1566542\\\/21\\\/exai_bio_lockup%403x_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/\",\"name\":\"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220910005004\\\/en\\\/1566542\\\/21\\\/exai_bio_lockup%403x_%281%29.jpg\",\"datePublished\":\"2022-09-10T11:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220910005004\\\/en\\\/1566542\\\/21\\\/exai_bio_lockup%403x_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220910005004\\\/en\\\/1566542\\\/21\\\/exai_bio_lockup%403x_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer - Pharma Trend","og_description":"\u2013 Poster presentation at the 2022 Annual Meeting of the European Society of Medical Oncology (ESMO), Paris, France PALO ALTO, Calif.–(BUSINESS WIRE)–#innovation–Exai Bio, a next-generation liquid biopsy company, and researchers at UCSF are presenting data from a new study in a poster entitled \u201cSerum-based colorectal cancer detection using orphan noncoding RNAs\u201d at the 2022 European ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-10T11:01:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220910005004\/en\/1566542\/21\/exai_bio_lockup%403x_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer","datePublished":"2022-09-10T11:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/"},"wordCount":624,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220910005004\/en\/1566542\/21\/exai_bio_lockup%403x_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/","url":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/","name":"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220910005004\/en\/1566542\/21\/exai_bio_lockup%403x_%281%29.jpg","datePublished":"2022-09-10T11:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220910005004\/en\/1566542\/21\/exai_bio_lockup%403x_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220910005004\/en\/1566542\/21\/exai_bio_lockup%403x_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exai-bio-presents-data-demonstrating-that-its-novel-rna-based-liquid-biopsy-platform-has-potential-for-early-detection-and-monitoring-of-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48204"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48204\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}